

## The Spanish Agency of Medicines and Medical Devices gives their approval to PharmaMar's new facilities

- **PharmaMar gains approval to expand its facilities to accommodate new logistical processes.**

**Madrid, 5<sup>th</sup> of December, 2018** – The Spanish Agency of Medicines and Medical Devices has authorized PharmaMar's (MSE:PHM) new facilities intended to improve production processes and designed to accelerate manufacturing and improve yields in the face of new potential needs.

This new authorization is to be added to those already existing at PharmaMar's facilities, that also have the approval from the European Medicines Agency (EMA), the US FDA and the Japanese agency (NIHS) for the production of the active pharmaceutical ingredients (API) of their compounds.

### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several ty-pes of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

### **Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127

Miguel Martínez-Cava – Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464

Phone: +34 918466000



**Investor Relations:**

Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)